Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors

Abstract

The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more foreign genes inserted according to the invention, a cell containing the cDNA, a plasmid comprising the cDNA, a cell containing the plasmid, a cell containing the recombinant antigenomic RNA, and a recombinant NDV containing the recombinant antigenomic RNA of the invention, such as a recombinant NDV carrying one or more foreign genes recovered from transcription of the cDNA or the plasmid in a competent cell. The recombinant NDV carrying the one or more foreign genes can be used as a vaccine or vaccine vector.

1 . An antigenomic RNA of Newcastle disease virus, comprising NP gene, P gene, M gene, F gene, HN gene and L gene in this order from a 5′ to 3′ direction, said antigenomic RNA further comprising n foreign nucleotide complexes inserted (a) before the NP gene, (b) between the P and M genes, and/or (c) between the HN and L genes, wherein n is 1, 2, 3 or 4; 
 each of the foreign nucleotide complexes comprising a Newcastle disease virus gene start sequence, an open reading frame of a foreign gene and a Newcastle disease virus gene end sequence in this order from the 5′ to 3′ direction, wherein the foreign gene is a gene not found naturally in the Newcastle disease virus; and  
 wherein when 2, 3 or 4 foreign nucleotide complexes are inserted together before the NP gene, between the P and M genes, or between the HN and L genes, the foreign nucleotide complexes are sequentially linked directly or indirectly.  
 
     
     
         2 . The antigenome RNA of  claim 1 , wherein n is 2, 3 or 4 and the foreign nucleotide complexes are different.  
     
     
         3 . The antigenome RNA of  claim 1 , wherein n is 2, 3 or 4 and the foreign nucleotide complexes are the same.  
     
     
         4 . The antigenome RNA of  claim 1 , wherein n is 1 or 2.  
     
     
         5 . The antigenome RNA of  claim 4 , wherein n is 2 and the foreign nucleotide complexes are different.  
     
     
         6 . The antigenome RNA of  claim 4 , wherein n is 2 and the foreign nucleotide complexes are the same.  
     
     
         7 . The antigenome RNA of  claim 1 , wherein the length of the open reading frame of the foreign gene is no more than about 3000 nucleotides.  
     
     
         8 . The antigenome RNA of  claim 7 , wherein the length of the open reading frame of the foreign gene is no more than about 1500 nucleotides.  
     
     
         9 . The antigenome RNA of  claim 8 , wherein the length of the open reading frame of the foreign gene is no more than about 1000 nucleotides.  
     
     
         10 . The antigenome RNA of  claim 9 , wherein the length of the open reading frame of the foreign gene is no more than about 800 nucleotides.  
     
     
         11 . The antigenome RNA of  claim 10 , wherein the length of the open reading frame of the foreign gene is no more than about 500 nucleotides.  
     
     
         12 . The antigenome RNA of  claim 11 , wherein the length of the open reading frame of the foreign gene is no more than about 300 nucleotides.  
     
     
         13 . The antigenome RNA of  claim 1 , wherein 2, 3 or 4 foreign nucleotide complexes are inserted together before the NP gene, between the P and M genes, or between the HN and L genes, the sequentially linked foreign nucleotide complexes having a combined length of no more than about 5000 nucleotides.  
     
     
         14 . The antigenomic RNA of  claim 13 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 2000 nucleotides.  
     
     
         15 . The antigenomic RNA of  claim 14 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 1000 nucleotides.  
     
     
         16 . The antigenomic RNA of  claim 15 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 800 nucleotides.  
     
     
         17 . The antigenomic RNA of  claim 1 , wherein the foreign genes of the foreign nucleotide complexes are selected from the group consisting of genes encoding chloramphenical acetyltransferase, green fluorescent protein, an avian cytokine, and an immunogenic protein of a virus selected from the group consisting of influenza virus, infectious bursal disease virus, rotavirus, infectious bronchitis virus, infectious laryngotracheitis virus, chicken anemia virus, Marek's disease virus, avian leukosis virus, avian adenovirus, and avian pneumovirus.  
     
     
         18 . The antigenomic RNA of  claim 1 , wherein the foreign genes of the foreign nucleotide complexes encode chloramphenical acetyltransferase.  
     
     
         19 . The antigenomic RNA of  claim 1 , wherein the foreign genes of the foreign nucleotide complexes encode the same or different avian cytokines.  
     
     
         20 . The antigenomic RNA of  claim 19 , wherein the avian cytokines are avian interleukins.  
     
     
         21 . The antigenomic RNA of  claim 20 , wherein the avian cytokines are avian IL-2 and/or IL-4.  
     
     
         22 . The antigenomic RNA of  claim 1 , wherein the foreign genes of the foreign nucleotide complexes encode an immunogenic protein of the same or different viruses selected from the group consisting of influenza virus, infectious bursal disease virus, rotavirus, infectious bronchitis virus, infectious laryngotracheitis virus, chicken anemia virus, Marek's disease virus, avian leukosis virus, avian adenovirus and avian pneumovirus.  
     
     
         23 . The antigenomic RNA of  claim 1 , wherein the n foreign nucleotide complexes are inserted (a) before the NP gene, and/or (b) between the P and M genes.  
     
     
         24 . The antigenomic RNA of  claim 23 , wherein the n foreign nucleotide complexes are inserted before the NP gene.  
     
     
         25 . The antigenome RNA of  claim 24 , wherein 2, 3 or 4 foreign nucleotide complexes are inserted together before the NP gene, the sequentially linked foreign nucleotide complexes having a combined length of no more than about 4000 nucleotides.  
     
     
         26 . The antigenomic RNA of  claim 25 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 2000 nucleotides.  
     
     
         27 . The antigenomic RNA of  claim 26 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 1000 nucleotides.  
     
     
         28 . The antigenomic RNA of  claim 27 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 800 nucleotides.  
     
     
         29 . The antigenomic RNA of  claim 23 , wherein the n foreign nucleotide complexes are inserted between the P and M genes.  
     
     
         30 . The antigenomic RNA of  claim 29 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 4000 nucleotides.  
     
     
         31 . The antigenomic RNA of  claim 30 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 2000 nucleotides.  
     
     
         32 . The antigenomic RNA of  claim 31 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 1000 nucleotides.  
     
     
         33 . The antigenomic RNA of  claim 32 , wherein the sequentially linked foreign nucleotide complexes have a combined length of no more than about 800 nucleotides.  
     
     
         34 . The antigenomic RNA of  claim 18 , wherein n is 1.  
     
     
         35 . The antigenomic RNA of  claim 19 , wherein n is 1.  
     
     
         36 . The antigenomic RNA of  claim 22 , wherein n is 1.  
     
     
         37 . The antigenomic RNA of  claim 24 , wherein n is 1.  
     
     
         38 . The antigenomic RNA of  claim 37 , wherein the open reading frame of the foreign gene encodes chloramphenicol acetyltransferase.  
     
     
         39 . The antigenomic RNA of  claim 37 , wherein the open reading frame of the foreign gene encodes an avian cytokine.  
     
     
         40 . The antigenomic RNA of  claim 39 , wherein the avian cytokine is an avian interleukin.  
     
     
         41 . The antigenomic RNA of  claim 40 , wherein the avian interleukin is IL-2 or IL-4.  
     
     
         42 . The antigenomic RNA of  claim 1 , having a length of m nucleotides, wherein m is a multiple of 6.  
     
     
         43 . The antigenomic RNA of  claim 1 , wherein at least one of the foreign nucleotide complexes contain foreign gene encoding an immunogenic protein of a non-avian pathogen.  
     
     
         44 . The antigenomic RNA of  claim 43 , wherein the non-avian pathogen is a virus selected from the group consisting of influenza virus, SARS-causing virus, human respiratory syncytial virus, human immunodeficiency virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, poliovirus, rabies virus, Hendra virus, Nipah virus, human parainfluenza 3 virus, measles virus, mumps virus, Ebola virus, Marburg virus, West Nile virus, Japanese encephalitis virus, Dengue virus, Hantavirus, Rift Valley fever virus, Lassa fever virus, herpes simplex virus and yellow fever virus.  
     
     
         45 . A cDNA encoding the antigenomic RNA of  claim 1 .  
     
     
         46 . A plasmid comprising the cDNA of  claim 45 .  
     
     
         47 . A cell comprising the cDNA of  claim 45 .  
     
     
         48 . A cell comprising the plasmid of  claim 46 .  
     
     
         49 . A cell comprising the antigenomic RNA of  claim 1 .  
     
     
         50 . A recombinant Newcastle disease virus produced by a process comprising the following steps: 
 (i) providing cells capable of synthesizing T7 RNA polymerase;    (ii) transfecting the cells with a plasmid comprising the cDNA encoding the antigenomic RNA of  claim 1 , a plasmid encoding NP protein, a plasmid encoding P protein, and a plasmid encoding L protein to obtain transfected cells in a medium; and thereafter    (iii) isolating Newcastle disease virus from a supernatant of the medium of step (ii) to obtain the recombinant Newcastle disease virus.    
     
     
         51 . The recombinant Newcastle disease virus of  claim 50 , wherein the cells capable of synthesizing T7 RNA polymerase provided in step (i) are from a cell line expressing T7 RNA polymerase.  
     
     
         52 . The recombinant Newcastle disease virus of  claim 50 , wherein the cells capable of synthesizing T7 RNA polymerase provided in step (i) are plant cells.  
     
     
         53 . The recombinant Newcastle disease virus of  claim 50 , wherein the cells capable of synthesizing T7 RNA polymerase provided in step (i) are mammalian cells.  
     
     
         54 . The recombinant Newcastle disease virus of  claim 50 , wherein the cells capable of synthesizing T7 RNA polymerase provided in step (i) are avian cells.  
     
     
         55 . The recombinant Newcastle disease virus of  claim 50 , wherein the cells capable of synthesizing T7 RNA polymerase provided in step (i) are HEp-2 cells infected with a virus that can synthesize T7 RNA polymerase.  
     
     
         56 . The recombinant Newcastle disease virus of  claim 55 , wherein the virus is a vaccinia virus.  
     
     
         57 . A recombinant Newcastle disease virus produced by a process comprising the following steps: 
 (i) providing cells capable of synthesizing T7 RNA polymerase;    (ii) transfecting the cells with a plasmid comprising the cDNA encoding the antigenomic RNA of  claim 18 , a plasmid encoding NP protein, a plasmid encoding P protein, and a plasmid encoding L protein to obtain transfected cells in a medium; and thereafter    (iii) isolating Newcastle disease virus from a supernatant of the medium of step (ii) to obtain the recombinant Newcastle disease virus.    
     
     
         58 . A recombinant Newcastle disease virus produced by a process comprising the following steps: 
 (i) providing cells capable of synthesizing T7 RNA polymerase;    (ii) transfecting the cells with a plasmid comprising the cDNA encoding the antigenomic RNA of  claim 19 , a plasmid encoding NP protein, a plasmid encoding P protein, and a plasmid encoding L protein to obtain transfected cells in a medium; and thereafter    (iii) isolating Newcastle disease virus from a supernatant of the medium of step (ii) to obtain the recombinant Newcastle disease virus.    
     
     
         59 . A recombinant Newcastle disease virus produced by a process comprising the following steps: 
 (i) providing cells capable of synthesizing T7 RNA polymerase;    (ii) transfecting the cells with a plasmid comprising the cDNA encoding the antigenomic RNA of  claim 22 , a plasmid encoding NP protein, a plasmid encoding P protein, and a plasmid encoding L protein to obtain transfected cells in a medium; and thereafter    (iii) isolating Newcastle disease virus from a supernatant of the medium of step (ii) to obtain the recombinant Newcastle disease virus.    
     
     
         60 . A recombinant Newcastle disease virus produced by a process comprising the following steps: 
 (i) providing cells capable of synthesizing T7 RNA polymerase;    (ii) transfecting the cells with a plasmid comprising the cDNA encoding the antigenomic RNA of  claim 43 , a plasmid encoding NP protein, a plasmid encoding P protein, and a plasmid encoding L protein to obtain transfected cells in a medium; and thereafter    (iii) isolating Newcastle disease virus from a supernatant of the medium of step (ii) to obtain the recombinant Newcastle disease virus.    
     
     
         61 . A method of vaccinating an avian animal against Newcastle disease, wherein the avian animal is in need of the vaccination, comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 50  to the avian animal.  
     
     
         62 . A method of vaccinating an avian animal against Newcastle disease, wherein the avian animal is in need of the vaccination, comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 57  to the avian animal.  
     
     
         63 . A method of treating an avian animal with an avian cytokine, wherein the avian animal is in need of the treatment, said method comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 58  to the avian animal.  
     
     
         64 . A method of immunizing an avian animal against an avian pathogen selected from the group consisting of influenza virus, infectious bursal disease virus, rotavirus, infectious bronchitis virus, infectious laryngotracheitis virus, chicken anemia virus, Marek's disease virus, avian Leukosis virus, avian adenovirus and avian pneumovirus, wherein the avian animal is in need of the immunization, said method comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 59  to the avian animal, wherein the open reading frame of the foreign gene encodes an immunogenic protein of the avian pathogen against which the avian animal is immunized.  
     
     
         65 . A method of immunizing a mammal against a non-avian pathogen, wherein the mammal is in need of the immunization, said method comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 60  to the mammal, wherein the open reading frame of the foreign gene encodes an immunogenic protein of the non-avian pathogen against which the mammal is immunized.  
     
     
         66 . The method of  claim 65 , wherein the non-avian pathogen is selected from the group consisting of influenza virus, SARS-causing virus, human respiratory syncytial virus, human immunodeficiency virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, poliovirus, rabies virus, Hendra virus, Nipah virus, human parainfluenza 3 virus, measles virus, mumps virus, Ebola virus, Marburg virus, West Nile virus, Japanese encephalitis virus, Dengue virus, Hantavirus, Rift Valley fever virus, Lassa fever virus, herpes simplex virus and yellow fever virus.  
     
     
         67 . A process of making the antigenomic RNA of  claim 1 , comprising the following steps: 
 (i) providing a cDNA comprising NP gene, P gene, M gene, F gene, HN gene and L gene in this order, said cDNA further comprising n foreign nucleotide complexes inserted (a) before the NP gene, (b) between the P and M genes, and/or (c) between the HN and L genes, wherein n is 1, 2, 3 or 4;    each of the foreign nucleotide complexes comprising a Newcastle disease virus gene start sequence, an open reading frame of a foreign gene and a Newcastle disease virus gene end sequence in this order from the 5′ to 3′ direction, wherein the foreign gene is a gene not found naturally in the Newcastle disease virus;    wherein when n is 2, 3 or 4, the foreign nucleotide complexes are the same or different; and    wherein when 2, 3 or 4 foreign nucleotide complexes are inserted together before the NP gene, between the P and M genes, or between the HN and L genes, the foreign nucleotide complexes are sequentially linked directly or indirectly;    (ii) transcribing the cDNA to form a mixture containing an antigenomic RNA; and thereafter    (iii) isolating the antigenomic RNA.    
     
     
         68 . The antigenomic RNA of  claim 1 , wherein at least one of the foreign nucleotide complexes is inserted before the NP gene.  
     
     
         69 . The antigenomic RNA of  claim 1 , wherein at least one of the foreign nucleotide complexes is inserted before the NP gene and at least one of the foreign nucleotide complexes is inserted between the P and M genes.  
     
     
         70 . The antigenomic RNA of  claim 1 , wherein at least one of the foreign nucleotide complexes is inserted before the NP gene and at least one of the foreign nucleotide complexes is inserted between the HN and L genes.  
     
     
         71 . The antigenomic RNA of  claim 1 , wherein at least one of the foreign nucleotide complexes is inserted before the NP gene, at least one of the foreign nucleotide complexes is inserted between the P and M genes, and at least one of the foreign nucleotide complexes is inserted between the HN and L genes.  
     
     
         72 . The antigenomic RNA of  claim 1 , wherein at least one of the foreign nucleotide complexes is inserted between the P and M genes.  
     
     
         73 . The antigenomic RNA of  claim 1 , further comprising at least one intergenic region selected from the group consisting of a NP-P intergenic region between the NP and P genes, a P-M intergenic region between the P and M genes, a M-F intergenic region between the M and F genes, a F-HN intergenic region between the F and HN genes, and a HN-L intergenic region between the HN and L genes.  
     
     
         74 . The antigenomic RNA of  claim 1 , further comprising a NP-P intergenic region between the NP and P genes, a P-M intergenic region between the P and M genes, a M-F intergenic region between the M and F genes, a F-HN intergenic region between the F and HN genes, and a HN-L intergenic region between the HN and L genes.  
     
     
         75 . The antigenomic RNA of  claim 1 , wherein the foreign gene of at least one of the foreign nucleotide complexes encodes a tumor antigen.  
     
     
         76 . The antigenomic RNA of  claim 75 , wherein the tumor antigen is selected from the group consisting of pg100, MAGE1, MAGE3 and CDK4.  
     
     
         77 . A recombinant Newcastle disease virus comprising the antigenomic RNA of  claim 1 .  
     
     
         78 . A recombinant Newcastle disease virus comprising the antigenomic RNA of  claim 18 .  
     
     
         79 . A recombinant Newcastle disease virus comprising the antigenomic RNA of  claim 19 .  
     
     
         80 . A recombinant Newcastle disease virus comprising the antigenomic RNA of  claim 22 .  
     
     
         81 . A recombinant Newcastle disease virus comprising the antigenomic RNA of  claim 43 .  
     
     
         82 . A method of vaccinating an avian animal against Newcastle disease, wherein the avian animal is in need of the vaccination, comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 77  to the avian animal.  
     
     
         83 . A method of vaccinating an avian animal against Newcastle disease, wherein the avian animal is in need of the vaccination, comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 78  to the avian animal.  
     
     
         84 . A method of treating an avian animal with an avian cytokine, wherein the avian animal is in need of the treatment, said method comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 79  to the avian animal.  
     
     
         85 . A method of immunizing an avian animal against an avian pathogen selected from the group consisting of influenza virus, infectious bursal disease virus, rotavirus, infectious bronchitis virus, infectious laryngotracheitis virus, chicken anemia virus, Marek's disease virus, avian Leukosis virus, avian adenovirus and avian pneumovirus, wherein the avian animal is in need of the immunization, said method comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 80  to the avian animal, wherein the open reading frame of the foreign gene encodes an immunogenic protein of the avian pathogen against which the avian animal is immunized.  
     
     
         86 . A method of immunizing a mammal against a non-avian pathogen, wherein the mammal is in need of the immunization, said method comprising administering an effective amount of the recombinant Newcastle disease virus of  claim 81  to the mammal, wherein the open reading frame of the foreign gene encodes an immunogenic protein of the non-avian pathogen against which the mammal is immunized.  
     
     
         87 . The antigenomic RNA of  claim 1 , wherein at least one foreign nucleotide complex is inserted between the P and M genes and at least one foreign nucleotide complex is inserted before the NP gene.  
     
     
         88 . The antigenomic RNA of  claim 1 , wherein at least one foreign nucleotide complex is inserted between the P and M genes and at least one foreign nucleotide complex is inserted between the HN and L genes.